![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Sanofi-Aventis |
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00133731 |
The objective of this dose-ranging study is to determine the effects of several intravenous (IV) regimens of otamixaban on pharmacodynamic markers (including markers of thrombosis and coagulation markers), safety/tolerability, clinical efficacy and pharmacokinetics.
Condition | Intervention | Phase |
Angioplasty, Transluminal, Percutaneous Coronary |
Drug: Otamixaban (XRP0673) Drug: Unfractionated Heparin Procedure: Percutaneous Coronary Intervention |
Phase II |
MedlinePlus related topics: | Blood Thinners |
Drug Information available for: | Heparin Antithrombin III Otamixaban |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Safety Study |
Official Title: | A Multinational, Randomized, Double-Blind, Double-Dummy, Exploratory, Parallel Group, Dose-Ranging Phase II Study to Evaluate Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Several Intravenous Regimens of Factor Xa Inhibitor Otamixaban (XRP0673), in Comparison to Intravenous Unfractionated Heparin, in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
![]() |
Show 89 Study Locations |
Sanofi-Aventis |
Study Director: | ICD CSD | Sanofi-Aventis |
Related Info 
![]()   |
Responsible Party: | sanofi-aventis ( ICD Study Director ) |
Study ID Numbers: | DRI6199, XRP0673 |
First Received: | August 23, 2005 |
Last Updated: | July 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00133731 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
![]() |